{"product_id":"elmd-vrio-analysis","title":"Electromed, Inc. (ELMD): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlocking sustainable competitive advantage is the ultimate goal, and our deep-dive VRIO analysis of Electromed, Inc. (ELMD) reveals precisely where its core strengths lie - assessing the Value, Rarity, Inimitability, and Organization of its key resources, as summarized by \u0026amp;O4\u0026amp;. Discover the critical factors driving Electromed, Inc. (ELMD)'s market position and what it means for its future success by reading the full breakdown below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eElectromed, Inc. (ELMD) - VRIO Analysis: SmartVest® HFCWO Technology and Intellectual Property\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re analyzing Electromed, Inc. (ELMD) and trying to figure out what keeps their SmartVest® High-Frequency Chest Wall Oscillation (HFCWO) technology ahead of the curve, especially when they are competing against giants. Honestly, the numbers from fiscal year 2025 tell a compelling story about their focus.\u003c\/p\u003e\n\n\u003cp\u003eThe direct takeaway is that Electromed’s singular focus on HFCWO, backed by proprietary tech and clinical evidence, currently grants them a sustained competitive advantage, evidenced by their \u003cstrong\u003e17.0%\u003c\/strong\u003e revenue growth in FY 2025.\u003c\/p\u003e\n\n\u003ch3\u003eValue: Driving Revenue Through Specialized Therapy\u003c\/h3\u003e\n\u003cp\u003eThe SmartVest® system delivers specialized airway clearance therapy for chronic lung conditions like bronchiectasis. This isn't just a nice feature; it’s what’s driving the top line. For the full fiscal year 2025 ending June 30, 2025, Electromed posted net revenues of \u003cstrong\u003e$64.0 million\u003c\/strong\u003e, which was a \u003cstrong\u003e17.0%\u003c\/strong\u003e increase over the prior year’s \u003cstrong\u003e$54.7 million\u003c\/strong\u003e. This growth shows the market values the efficacy of their specific solution. The clinical data backs this up, showing benefits like a \u003cstrong\u003e59%\u003c\/strong\u003e reduction in hospitalizations and \u003cstrong\u003e57%\u003c\/strong\u003e fewer antibiotics for some patients. That’s real value translated into fewer healthcare events.\u003c\/p\u003e\n\n\u003ch3\u003eRarity: The Pure-Play Focus\u003c\/h3\u003e\n\u003cp\u003eIs this technology rare? Not entirely, as competitors like Baxter (through Hill-Rom), Philips, and Tactile Systems Technology all operate in the broader airway clearance space. However, Electromed is the only one singularly dedicated to HFCWO therapy. While Baxter and Philips don't even report their specific airway clearance sales, Electromed’s entire business is built around this one modality. This focus means all their R\u0026amp;D and sales efforts are concentrated here, which is a rarity among their diversified rivals. It’s a classic niche dominance play.\u003c\/p\u003e\n\n\u003ch3\u003eImitability: Difficult Due to IP and Data Moats\u003c\/h3\u003e\n\u003cp\u003eTrying to copy the SmartVest® system isn't as simple as reverse-engineering the hardware. The core technology is protected by established patents, including their patented single-hose design, which they argue offers more comfortable oscillation delivery. More importantly, they have decades of clinical data - multiple published outcome studies - demonstrating efficacy in reducing exacerbations and improving quality of life. Building that body of evidence takes years and significant investment; you can’t just download that kind of credibility. If onboarding takes 14+ days, churn risk rises, but imitation of the core value proposition is slow.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization: High Alignment with Strategy\u003c\/h3\u003e\n\u003cp\u003eA great asset is useless if the company isn't organized to exploit it. Electromed demonstrates high organization by consistently investing in market development and operational efficiency. For instance, during FY 2025, the company successfully executed a \u003cstrong\u003e$10.0 million\u003c\/strong\u003e share repurchase program, showing capital discipline. They also strengthened infrastructure by launching a new CRM system and expanding their direct sales team to better educate physicians and patients on the SmartVest advantages. They are definitely structured to push their unique offering.\u003c\/p\u003e\n\n\u003ch3\u003eCompetitive Advantage Scoring\u003c\/h3\u003e\n\u003cp\u003eHere’s the quick math on where the SmartVest® technology stands based on the VRIO assessment. What this estimate hides is the risk of a large competitor deciding to focus heavily on HFCWO.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment\u003c\/td\u003e\n\u003ctd\u003eImplication for Electromed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue (V)\u003c\/td\u003e\n\u003ctd\u003eYes (Drives \u003cstrong\u003e17.0%\u003c\/strong\u003e growth in FY2025)\u003c\/td\u003e\n\u003ctd\u003eCompetitive Parity to Temporary Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity (R)\u003c\/td\u003e\n\u003ctd\u003eYes (Only pure-play HFCWO focus)\u003c\/td\u003e\n\u003ctd\u003eTemporary Competitive Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImitability (I)\u003c\/td\u003e\n\u003ctd\u003eDifficult (Patents \u0026amp; Clinical Data)\u003c\/td\u003e\n\u003ctd\u003ePotential for Sustained Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization (O)\u003c\/td\u003e\n\u003ctd\u003eHigh (Executes buybacks, expands sales)\u003c\/td\u003e\n\u003ctd\u003eRealizing Sustained Advantage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOverall Advantage\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSustained Competitive Advantage\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOutperformance likely if focus is maintained\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFinance: draft 13-week cash view by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eElectromed, Inc. (ELMD) - VRIO Analysis: Direct-to-Patient Homecare Sales Model\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eDirect-to-Patient Homecare Sales Model\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Allows for higher net revenue per device and direct patient relationship management, evidenced by homecare revenue growth of \u003cstrong\u003e18.5%\u003c\/strong\u003e in Q1 FY2025. Home Care Revenue for Q1 FY2025 was \u003cstrong\u003e$13.2 million\u003c\/strong\u003e, up from \u003cstrong\u003e$11.2 million\u003c\/strong\u003e in Q1 FY2024.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; many competitors rely more heavily on hospital channels, making this direct focus somewhat unique.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Costly; requires building out a specialized, trained field sales force and managing complex reimbursement in-house.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the sales force expansion and high revenue-per-rep metrics show strong exploitation of this model.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; while effective now, larger players could shift focus to replicate this model over time.\u003c\/p\u003e\n\n\u003cp\u003eThe operational scale and productivity of the direct sales model are detailed below:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ1 FY2025\u003c\/td\u003e\n\u003ctd\u003eFY 2025\u003c\/td\u003e\n\u003ctd\u003eQ3 FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Sales Representatives\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e53\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e55\u003c\/strong\u003e (Q4 FY2025 end)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e51\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnualized Homecare Revenue per Direct Sales Representative\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$985,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1,058,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$969,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Homecare Revenue (Quarterly\/Annual)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$57.3 million\u003c\/strong\u003e (Annual)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFurther statistical data points supporting the model's execution include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Field Sales Employees at Q1 FY2025 quarter-end: \u003cstrong\u003e60\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAnnualized Homecare Revenue per Direct Sales Representative target range for FY2025: \u003cstrong\u003e$900,000\u003c\/strong\u003e to \u003cstrong\u003e$1,000,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDirect Homecare Revenue growth for FY 2025 year-over-year: \u003cstrong\u003e15.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDirect Homecare Revenue in Q1 FY2026: \u003cstrong\u003e$14.9 million\u003c\/strong\u003e, a year-over-year increase of \u003cstrong\u003e12.7%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eDirect Sales Force in Q1 FY2026: \u003cstrong\u003e57\u003c\/strong\u003e representatives.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eElectromed, Inc. (ELMD) - VRIO Analysis: High Gross Profit Margin\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003cstrong\u003eValue\u003c\/strong\u003e: Consistently high margins, reaching \u003cstrong\u003e78.3%\u003c\/strong\u003e in Q1 FY2025, provide significant operating leverage for reinvestment or profit.\n\u003c\/p\u003e\n\u003cp\u003e\nThe Q1 FY2025 Gross Profit was \u003cstrong\u003e$11.5 million\u003c\/strong\u003e on Net Revenues of \u003cstrong\u003e$14.7 million\u003c\/strong\u003e, representing a \u003cstrong\u003e78.3%\u003c\/strong\u003e gross margin, an increase from \u003cstrong\u003e77.1%\u003c\/strong\u003e in Q1 FY2024. This margin performance translated to an Operating Income of \u003cstrong\u003e$1.9 million\u003c\/strong\u003e, or \u003cstrong\u003e13.2%\u003c\/strong\u003e of revenue, a substantial increase from \u003cstrong\u003e1.2%\u003c\/strong\u003e in the prior year's comparable quarter.\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ1 FY2025 Value\u003c\/th\u003e\n\u003cth\u003eQ1 FY2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e78.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e77.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Income Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003cstrong\u003eRarity\u003c\/strong\u003e: Rare; this margin level is high for a medical device company, especially one with \u003cstrong\u003eno debt\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDebt: \u003cstrong\u003e$0\u003c\/strong\u003e as of March 31, 2025.\u003c\/li\u003e\n\u003cli\u003eDebt: \u003cstrong\u003e$0\u003c\/strong\u003e as of December 31, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003cstrong\u003eImitability\u003c\/strong\u003e: Difficult; stems from pricing power and efficient manufacturing\/reimbursement processes.\n\u003c\/p\u003e\n\u003cp\u003e\nThe increase in gross margin rate was primarily driven by a \u003cstrong\u003ehigher average net revenue per device\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAnnualized Home Care Revenue per Direct Sales Representative reached \u003cstrong\u003e$985,000\u003c\/strong\u003e in Q1 FY2025, up from \u003cstrong\u003e$876,000\u003c\/strong\u003e in Q1 FY2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003cstrong\u003eOrganization\u003c\/strong\u003e: High; management explicitly links margin improvement to \u003cstrong\u003ehigher average net revenue per device\u003c\/strong\u003e.\n\u003c\/p\u003e\n\u003cp\u003e\nManagement commentary highlights that the gross margin rate increase was primarily driven by a \u003cstrong\u003ehigher average net revenue per device\u003c\/strong\u003e. The company also increased its direct sales force to \u003cstrong\u003e53 reps\u003c\/strong\u003e by the end of Q1 FY2025.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e: Sustained; a key indicator of pricing power and cost control.\n\u003c\/p\u003e\n\u003cp\u003e\nThe company achieved its eighth consecutive quarter of year-over-year revenue and profit growth in Q1 FY2025. The Gross Profit Dollar increase was due to increased revenue volume and a \u003cstrong\u003ehigher average net revenue per device\u003c\/strong\u003e.\n\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eElectromed, Inc. (ELMD) - VRIO Analysis: Strong, Debt-Free Balance Sheet\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cp\u003e\n\u003cstrong\u003eValue:\u003c\/strong\u003e Provides financial flexibility, allowing for $10.0 million in share repurchases during FY 2025 and weathering market shocks.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; as of June 30, 2025, the company had no debt and $15.3 million in cash.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eImitability:\u003c\/strong\u003e Easy to achieve, but hard to maintain while growing; requires disciplined capital allocation.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the board approved buybacks, showing management is organized to use cash strategically.\n\u003c\/p\u003e\n\u003cp\u003e\n\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; cash reserves can be depleted, but the no-debt status is a strong current advantage.\n\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eBalance Sheet and Cash Flow Metrics\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAs of June 30, 2025 (FY End)\u003c\/th\u003e\n\u003cth\u003eAs of September 30, 2025 (Q1 FY2026 End)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Cash\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.1 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNo debt\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNo debt\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccounts Receivable\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$24.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorking Capital\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$34.6 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$35.8 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Shareholders' Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$44.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003cstrong\u003eFinancial Activity Details\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\nShare repurchases totaled \u003cstrong\u003e$10.0 million\u003c\/strong\u003e throughout FY 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nCash provided by operations totaled a record \u003cstrong\u003e$11.4 million\u003c\/strong\u003e in FY 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nShare repurchases of \u003cstrong\u003e$1.0 million\u003c\/strong\u003e occurred in the three months ended September 30, 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nThe board approved a stock repurchase authorization of \u003cstrong\u003e$10 million\u003c\/strong\u003e in Q1 FY 2026.\n\u003c\/li\u003e\n\u003cli\u003e\nOperating cash flow increased to \u003cstrong\u003e$7.5 million\u003c\/strong\u003e for the nine months ended March 31, 2025.\n\u003c\/li\u003e\n\u003cli\u003e\nShare repurchases of approximately \u003cstrong\u003e$6.3 million\u003c\/strong\u003e occurred in the nine months ended March 31, 2025.\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eElectromed, Inc. (ELMD) - VRIO Analysis: Consistent Double-Digit Growth Track Record\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Demonstrates reliable execution and market acceptance, achieving \u003cstrong\u003eeleven consecutive quarters\u003c\/strong\u003e of year-over-year revenue and operating income growth.\u003c\/p\u003e\n\n\u003cp\u003eThe sustained growth is evidenced by recent fiscal year 2025 performance:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFiscal Quarter\u003c\/th\u003e\n\u003cth\u003eNet Revenue (Millions)\u003c\/th\u003e\n\u003cth\u003eYoY Revenue Growth\u003c\/th\u003e\n\u003cth\u003eOperating Income (Millions)\u003c\/th\u003e\n\u003cth\u003eYoY Op. Income Growth\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 FY 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.4\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e17.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e30.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ3 FY 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$15.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e13.1%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.1\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e16.2%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ2 FY 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$16.3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e18.7%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.5\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e12.3%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 FY 2025\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.7\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19.0%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFull Fiscal Year 2025 results included Net Revenue of a record \u003cstrong\u003e$64.0 million\u003c\/strong\u003e, a \u003cstrong\u003e17.0%\u003c\/strong\u003e increase YoY, and Operating Income of a record \u003cstrong\u003e$9.7 million\u003c\/strong\u003e, a \u003cstrong\u003e46.8%\u003c\/strong\u003e increase YoY.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Rare; few micro-cap medical device firms maintain this consistency, especially through FY 2025. The direct homecare business revenue grew \u003cstrong\u003e15.7%\u003c\/strong\u003e to \u003cstrong\u003e$57.3 million\u003c\/strong\u003e in FY 2025.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Impossible; past performance is path-dependent and cannot be copied directly. The growth is linked to specific organizational investments:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eField sales employees totaled \u003cstrong\u003e62\u003c\/strong\u003e at year-end FY 2025, with \u003cstrong\u003e55\u003c\/strong\u003e being direct sales representatives.\u003c\/li\u003e\n\u003cli\u003eAnnualized homecare revenue per weighted average direct sales representative in Q2 FY 2025 was \u003cstrong\u003e$1,077,000\u003c\/strong\u003e, exceeding the target range of $900,000 to $1,000,000.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; this is a direct result of coordinated sales, marketing, and reimbursement efforts. The balance sheet strength supports continued investment:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAs of June 30, 2025, Electromed held \u003cstrong\u003e$15.3 million\u003c\/strong\u003e in cash and had \u003cstrong\u003eno debt\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eWorking capital was \u003cstrong\u003e$34.6 million\u003c\/strong\u003e as of June 30, 2025.\u003c\/li\u003e\n\u003cli\u003eCash provided by operations totaled a record \u003cstrong\u003e$11.4 million\u003c\/strong\u003e in FY 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained; a history of execution builds investor and physician trust. The company repurchased \u003cstrong\u003e$10.0 million\u003c\/strong\u003e of its common stock throughout FY 2025.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eElectromed, Inc. (ELMD) - VRIO Analysis: High Sales Force Productivity\n\u003c\/h2\u003e\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eMaximizes return on sales investment, with annualized homecare revenue per direct sales representative hitting \u003cstrong\u003e$985,000\u003c\/strong\u003e in Q1 FY2025. This compares to \u003cstrong\u003e$876,000\u003c\/strong\u003e in Q1 FY2024. The Q1 FY2025 Net Revenue was \u003cstrong\u003e$14.7 million\u003c\/strong\u003e, a \u003cstrong\u003e19.0%\u003c\/strong\u003e increase year-over-year.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eQ1 FY2025\u003c\/td\u003e\n\u003ctd\u003eQ1 FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnualized Homecare Revenue per Direct Sales Representative\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$985,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$876,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Sales Representatives (Count)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e53\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eData not explicitly available for Q1 FY2024 count\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Field Sales Force Employees (Count)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e60\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eData not explicitly available for Q1 FY2024 count\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eRare; this metric of \u003cstrong\u003e$985,000\u003c\/strong\u003e per rep in Q1 FY2025 is at the high end of Electromed's increased annual target range of \u003cstrong\u003e$900,000 to $1,000,000\u003c\/strong\u003e. The subsequent Q1 FY2026 annualized revenue per rep reached \u003cstrong\u003e$1,052,000\u003c\/strong\u003e, within a new target range of \u003cstrong\u003e$1,000,000 to $1,100,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eCostly; requires effective training, high-quality leads, and a strong product value proposition. The company initiated an investment in a new CRM system during Q2 FY2025 to further enhance commercial team productivity.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross Profit Margin in Q1 FY2025 was \u003cstrong\u003e78.3%\u003c\/strong\u003e of net revenues, up from \u003cstrong\u003e77.1%\u003c\/strong\u003e in Q1 FY2024.\u003c\/li\u003e\n\u003cli\u003eOperating Income in Q1 FY2025 was \u003cstrong\u003e$1.9 million\u003c\/strong\u003e, or \u003cstrong\u003e13.2%\u003c\/strong\u003e of revenue, compared to \u003cstrong\u003e$0.1 million\u003c\/strong\u003e, or \u003cstrong\u003e1.2%\u003c\/strong\u003e of revenue in Q1 FY2024.\u003c\/li\u003e\n\u003cli\u003eNet Income in Q1 FY2025 was \u003cstrong\u003e$1.5 million\u003c\/strong\u003e, or \u003cstrong\u003e$0.16\u003c\/strong\u003e per diluted share.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; the company actively manages and expands its sales territories and reps. The total number of sales territories increased to \u003cstrong\u003e57\u003c\/strong\u003e by the end of Q1 FY2025. The direct sales force totaled \u003cstrong\u003e53\u003c\/strong\u003e reps in Q1 FY2025, growing to an average of \u003cstrong\u003e57\u003c\/strong\u003e reps in Q1 FY2026.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eQ1 FY2025 Direct Sales Representatives: \u003cstrong\u003e53\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ1 FY2025 Sales Territories: \u003cstrong\u003e57\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFY 2025 Direct Sales Representatives (Year End): \u003cstrong\u003e55\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eQ1 FY2026 Average Direct Sales Representatives: \u003cstrong\u003e57\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eTemporary; competitors can improve their own sales efficiency over time. The company repurchased approximately \u003cstrong\u003e$4.5 million\u003c\/strong\u003e of its common stock in Q1 FY2025 against a \u003cstrong\u003e$5 million\u003c\/strong\u003e authorization.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eElectromed, Inc. (ELMD) - VRIO Analysis: Established Reimbursement Pathways\n\u003c\/h2\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eEnsures patient access to the SmartVest® system, as both Medicare and private insurers provide coverage, splitting revenue about 50\/50.\u003c\/p\u003e\n\u003cp\u003eThe availability of reimbursement is an important consideration for health care professionals and patients.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eQ1 FY2025\u003c\/th\u003e\n\u003cth\u003eQ1 FY2024\u003c\/th\u003e\n\u003cth\u003eFY 2025\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$14.7 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$12.3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$64.0 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHomecare Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$13.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$11.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproximate Revenue per Patient\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eModerate; necessary for market entry, but Electromed has successfully navigated this for years in a mature segment.\u003c\/p\u003e\n\u003cp\u003eThe SmartVest System is reimbursed under HCPCS code \u003cstrong\u003eE0483\u003c\/strong\u003e for HFCWO devices.\u003c\/p\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eDifficult; securing and maintaining favorable reimbursement codes takes significant time and regulatory effort.\u003c\/p\u003e\n\u003cp\u003eMedicare allowable is about \u003cstrong\u003e$13,000\u003c\/strong\u003e, while state Medicaid's allowable range is between \u003cstrong\u003e$8,000\u003c\/strong\u003e and \u003cstrong\u003e$13,000\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eHigh; efficiencies in their reimbursement department contributed to Q1 FY2025 revenue growth.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eNet revenues grew \u003cstrong\u003e19.0%\u003c\/strong\u003e in Q1 FY2025.\u003c\/li\u003e\n\u003cli\u003eNet income in Q1 FY2025 was \u003cstrong\u003e$1.5 million\u003c\/strong\u003e, compared to \u003cstrong\u003e$0.2 million\u003c\/strong\u003e in Q1 FY2024.\u003c\/li\u003e\n\u003cli\u003eThe company employs a team of reimbursement specialists dedicated to managing insurance and payer relations.\u003c\/li\u003e\n\u003cli\u003eAnnualized homecare revenue per direct sales representative reached \u003cstrong\u003e$985,000\u003c\/strong\u003e in Q1 FY2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eSustained; a deep moat against new entrants who lack established payer relationships.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eElectromed, Inc. (ELMD) - VRIO Analysis: Inclusion in Russell 2000® and 3000® Indexes\n\u003c\/h2\u003e\n\n\u003cp\u003eInclusion in the Russell 2000® and 3000® Indexes is a significant event for Electromed, Inc. (ELMD), effective after the close of U.S. equity markets on \u003cstrong\u003eJune 27, 2025\u003c\/strong\u003e, as part of the 2025 annual reconstitution.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eIndex inclusion increases visibility to institutional investors and index funds, potentially boosting liquidity and valuation multiples. The Russell US Indexes, which include the Russell 2000® and 3000®, benchmark approximately \u003cstrong\u003e$10.6 trillion\u003c\/strong\u003e in assets.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eThis is a recent achievement, effective \u003cstrong\u003eJune 27, 2025\u003c\/strong\u003e, signaling broader market recognition. The Russell 2000 Index is composed of the bottom \u003cstrong\u003e2,000\u003c\/strong\u003e smallest companies in the Russell 3000 Index. The Russell 3000 Index measures the performance of the largest \u003cstrong\u003e3,000\u003c\/strong\u003e U.S. companies.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eThe inclusion is an external validation based on size and trading metrics determined by FTSE Russell's rules-based methodology, making it impossible for competitors to imitate the status itself. Eligibility requires a total market capitalization of US$\u003cstrong\u003e30 million\u003c\/strong\u003e or more on rank day.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThe company benefits passively from this external recognition. The company's financial performance leading up to the announcement included:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eRevenue: \u003cstrong\u003e$15.7 million\u003c\/strong\u003e (a \u003cstrong\u003e13.1%\u003c\/strong\u003e increase year-over-year).\u003c\/li\u003e\n\u003cli\u003eOperating Income: \u003cstrong\u003e$2.1 million\u003c\/strong\u003e (a \u003cstrong\u003e16.2%\u003c\/strong\u003e increase year-over-year).\u003c\/li\u003e\n\u003cli\u003eNet Income: \u003cstrong\u003e$1.9 million\u003c\/strong\u003e, or $\u003cstrong\u003e0.21\u003c\/strong\u003e per diluted share (a \u003cstrong\u003e26.7%\u003c\/strong\u003e increase year-over-year).\u003c\/li\u003e\n\u003cli\u003eGross Profit Margin: \u003cstrong\u003e78.0%\u003c\/strong\u003e (up from \u003cstrong\u003e74.8%\u003c\/strong\u003e).\u003c\/li\u003e\n\u003cli\u003eCash Position: \u003cstrong\u003e$15.2 million\u003c\/strong\u003e as of March 31, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e; index inclusion status can be lost if market cap or trading metrics decline below the required thresholds during subsequent annual reconstitutions. As of late 2025, Electromed’s Market Cap was reported around \u003cstrong\u003e$231.99 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eThe following table summarizes key financial and index-related statistics for Electromed, Inc. (ELMD):\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eContext\/Date\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndex Inclusion Date\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eJune 27, 2025\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEffective date for Russell 2000® and 3000® inclusion.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRussell US Indexes Assets Benchmarked\u003c\/td\u003e\n\u003ctd\u003eApproximately \u003cstrong\u003e$10.6 trillion\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eIndicates the scale of investment tracking these indexes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization (Recent)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$231.99 million\u003c\/strong\u003e to \u003cstrong\u003e$201.80 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReported market cap figures around late 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e52-Week Stock Price Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$17.73\u003c\/strong\u003e to \u003cstrong\u003e$35.56\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eReflects stock volatility.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice-to-Earnings (P\/E) Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e29.92\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eReported P\/E multiple.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Trading Volume (3 months)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e48.39K\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eIndicates typical daily liquidity.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimum Eligibility Market Cap for Russell Inclusion\u003c\/td\u003e\n\u003ctd\u003eUS$\u003cstrong\u003e30 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eThreshold for inclusion in the Russell US equity indexes.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRussell 2000 Holdings Count\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,951\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNumber of companies in the index as of November 30, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eElectromed, Inc. (ELMD) - VRIO Analysis: Niche Market Leadership in Specific Indications\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue: Deep focus on conditions like bronchiectasis and neuromuscular disorders allows for targeted marketing and clinical expertise.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSmartVest System is prescribed for patients with bronchiectasis, cystic fibrosis, and neuromuscular conditions such as cerebral palsy and Amyotrophic Lateral Sclerosis (ALS).\u003c\/li\u003e\n\u003cli\u003eBronchiectasis is believed to be the fastest growing diagnostic category for High-Frequency Chest Wall Oscillation (HFCWO) growth in the United States, showing an 8.7% increase in diagnosed patients between 2000 and 2007.\u003c\/li\u003e\n\u003cli\u003eEstimated net diagnosed Bronchiectasis prevalence in Medicare patients in 2021 exceeded 608,000.\u003c\/li\u003e\n\u003cli\u003eHFCWO penetration in the diagnosed Bronchiectasis population is estimated at ~15%.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity: Moderate; while the overall HFCWO market has players, Electromed is a specialist in these specific patient populations.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eElectromed positions itself as the only pure-play provider of HFCWO therapy.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability: Difficult; requires years of focused clinical engagement and physician trust within these specific communities.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe company has published studies demonstrating effectiveness of HFCWO in Bronchiectasis patients, showing decreased exacerbations requiring hospitalization and antibiotic use.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization: High; evidenced by targeted campaigns like the 'Triple Down on Bronchiectasis' initiative.\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganizational Metric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinicians Reached (Triple Down Campaign)\u003c\/td\u003e\n\u003ctd\u003eOver 10,000 clinicians or over 18,000 individuals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCampaign Engagement (Active Content Engagement)\u003c\/td\u003e\n\u003ctd\u003eMore than 3,000 actively engaged with content\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDedicated Landing Page Views\u003c\/td\u003e\n\u003ctd\u003eOver 31,000 views\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect Sales Representatives (Q3 FY2025)\u003c\/td\u003e\n\u003ctd\u003e55 (Up from 51 in prior year)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnualized Homecare Revenue Per Rep (Q2)\u003c\/td\u003e\n\u003ctd\u003e$1,077,000 (Above target range of $900,000 to $1,000,000)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage: Sustained; deep clinical expertise in a narrow field is hard for generalists to match.\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFinancial efficiency metrics support organizational strength:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGross Margin: 78.1% (Q4 2025) or 78.0% (Q3 FY2024).\u003c\/li\u003e\n\u003cli\u003eReturn on Equity (ROE): 19.02%.\u003c\/li\u003e\n\u003cli\u003eFinancial Position: No debt as of December 31, 2024.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIf onboarding takes 14+ days, churn risk rises, so keep those reimbursement efficiencies tight. Finance: draft 13-week cash view by Friday.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516157288597,"sku":"elmd-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/elmd-vrio-analysis.png?v=1740169352","url":"https:\/\/dcf-model.com\/products\/elmd-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}